Skip to the content
Seraxislogo darklogo light
  • Home
  • Technology
  • Pipeline
  • About
    • Leadership
    • Press Releases
    • In the News
    • Publications & Presentations
    • Contact Us
Search
Seraxis
  • Home
  • Technology
  • Pipeline
  • About
    • Leadership
    • Press Releases
    • In the News
    • Publications & Presentations
    • Contact Us
HomePress ReleaseSeraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit.
Press Release

Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit.

admin
April 25, 2023
View Press Release

About Seraxis, Inc.

Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes.

Share share
  • .face-icon{fill:#fff;}
  • .tw-icon{fill:#fff;}
  • .ln-icon{fill:#fff;}
  • .pn-icon{fill:#fff;}
Previous post
Seraxis announces Appointment of Chief Medical Officer, Dr. Paul Strumph.
Next post
Late-Breaking Results of a Preclinical Efficacy Study presented at ENDO 2023 show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia.

Related articles

Press Release
Seraxis announces Appointment of Chief Medical Officer, Dr. Paul Strumph.
admin
August 30, 2022
Press Release
Seraxis Inc. closed a Series B financing Round and enters into a collaboration with Medytox Inc.
admin
August 10, 2016
Press Release
Cell Therapy Startup, Seraxis, secures Series A Funding.
admin
April 8, 2013
Seraxis, Inc.

Seraxis, Inc | 20400 Century Blvd, Suite 150 | Germantown, MD 20874

Home

Technology

Publications & Presentations

Pipeline

About

Press Releases

Contact Us

© 2026 Seraxis, Inc. All Rights Reserved

Back to top Drag
w
  • Services
  • Careers
  • Contact Us